Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, zarnestra) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): North American intergroup study S0432.
Publication
, Conference
Erba, HP; Kopecky, KJ; Kirschbaum, MH; Tallman, MS; Larson, RA; Willman, CL; Slovak, ML; Gundacker, HM; Appelbaum, FR
Published in: ANNALS OF HEMATOLOGY
February 1, 2008
Duke Scholars
Published In
ANNALS OF HEMATOLOGY
EISSN
1432-0584
ISSN
0939-5555
Publication Date
February 1, 2008
Volume
87
Start / End Page
S57 / S59
Publisher
SPRINGER
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Erba, H. P., Kopecky, K. J., Kirschbaum, M. H., Tallman, M. S., Larson, R. A., Willman, C. L., … Appelbaum, F. R. (2008). Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, zarnestra) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): North American intergroup study S0432. In ANNALS OF HEMATOLOGY (Vol. 87, pp. S57–S59). SPRINGER.
Erba, H. P., K. J. Kopecky, M. H. Kirschbaum, M. S. Tallman, R. A. Larson, C. L. Willman, M. L. Slovak, H. M. Gundacker, and F. R. Appelbaum. “Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, zarnestra) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): North American intergroup study S0432.” In ANNALS OF HEMATOLOGY, 87:S57–59. SPRINGER, 2008.
Erba HP, Kopecky KJ, Kirschbaum MH, Tallman MS, Larson RA, Willman CL, et al. Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, zarnestra) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): North American intergroup study S0432. In: ANNALS OF HEMATOLOGY. SPRINGER; 2008. p. S57–9.
Erba, H. P., et al. “Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, zarnestra) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): North American intergroup study S0432.” ANNALS OF HEMATOLOGY, vol. 87, SPRINGER, 2008, pp. S57–59.
Erba HP, Kopecky KJ, Kirschbaum MH, Tallman MS, Larson RA, Willman CL, Slovak ML, Gundacker HM, Appelbaum FR. Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, zarnestra) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): North American intergroup study S0432. ANNALS OF HEMATOLOGY. SPRINGER; 2008. p. S57–S59.
Published In
ANNALS OF HEMATOLOGY
EISSN
1432-0584
ISSN
0939-5555
Publication Date
February 1, 2008
Volume
87
Start / End Page
S57 / S59
Publisher
SPRINGER
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology